863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort.
Saved in:
| Title: | 863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort. |
|---|---|
| Authors: | Cristea, M.C.1 (AUTHOR), Frankel, P.2 (AUTHOR), Synold, T.3 (AUTHOR), Stewart, D.B.1 (AUTHOR), Wang, E.1 (AUTHOR), Jung, A.4 (AUTHOR), Wilczynski, S.5 (AUTHOR), Tran, M.5 (AUTHOR), Konecny, G.E.6 (AUTHOR), Eng, M.7 (AUTHOR), Kilpatrick, L.8 (AUTHOR), Chen, Y-J.9 (AUTHOR), Glaser, S.9 (AUTHOR), Han, E.10 (AUTHOR), Dellinger, T.10 (AUTHOR), Hakim, A.10 (AUTHOR), Lee, S.10 (AUTHOR), Morgan, R.J.1 (AUTHOR), Rodriguez, L.10 (AUTHOR), Wakabayashi, M.10 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS639-S639. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2020.08.1002 |
